Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7009, no generic name available · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AZD7009, no generic name available | DRUG | - |
Inclusion Criteria: * Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity Exclusion Criteria: * Clinically significant sinus and/or AV node dysfun...
AZD7009 is an investigational small molecule being developed by AstraZeneca PLC for the treatment of atrial fibrillation. It is in Phase 2 clinical development. The drug has no generic name available.
AZD7009 is being studied for the treatment of atrial fibrillation, a cardiovascular condition. The Phase 2 trial specifically enrolled patients with this condition.
AZD7009 is in Phase 2 clinical development. There is one completed Phase 2 trial, and no active trials are currently listed for this drug.
The trial, NCT00255281, was a Phase 2 study titled 'Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation.' It was completed with 160 participants. The trial was randomized and double-blind, but had an uncontrolled design. It enrolled adults aged 18 and older of all sexes, and did not include healthy volunteers.
The Phase 2 trial for AZD7009 was conducted in multiple European countries: Denmark, Finland, Germany, Hungary, Netherlands, Norway, Poland, and Sweden.
Yes, the AZD7009 Phase 2 trial was randomized and double-blind. However, it used an uncontrolled design, meaning there was no comparator arm. The trial enrolled 160 participants.